Publications

Davies A, Conteduca V, Zoubeidi A, Beltran H.  2019.  Biological Evolution of Castration-resistant Prostate Cancer.. Eur Urol Focus. 5(2):147-154.

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H.  2018.  BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.. JCO Precis Oncol. 2

Conteduca V, Ku S-Y, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, Slade M, Gilbertson C, Manohar J, Sigouros M et al..  2021.  Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis.. NPJ Precis Oncol. 5(1):76.

Beltran H, Nanus DM, Sboner A, Mosquera JMiguel, Elemento O, Tagawa ST, Demichelis F, Romanel A, Conteduca V, Casiraghi N et al..  2020.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.. J Clin Invest. 130(4):1653-1668.

Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JMiguel, Elemento O et al..  2019.  Clinical features of neuroendocrine prostate cancer.. Eur J Cancer. 121:7-18.

Puca L, Gavyert K, Sailer V, Conteduca V, Dardenne E, Sigouros M, Isse K, Kearney M, Vosoughi A, Fernandez L et al..  2019.  Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer.. Sci Transl Med. 11(484)

Berger A, Brady NJ, Bareja R, Robinson B, Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X et al..  2019.  N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.. J Clin Invest. 129(9):3924-3940.

Conteduca V, Beltran H, Nanus DM, Tagawa ST, Mosquera JMiguel, Sboner A, Elemento O, Ku S-Y, Puca L, Slade M et al..  2020.  SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.. Mol Cancer Ther. 19(5):1157-1164.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.